MDX Medx Health Corp

MedX Health Corp. ("MedX" or the "Company") (TSX VENTURE:MDX) announced its
results for the three months ended March 31, 2014, which are also available on
SEDAR (www.sedar.com).


The Company reported a loss of $268,732, or $0.00 per share for the three months
ended March 31, 2014, compared with a loss of $348,668, or $0.01 per share for
three months ended March 31, 2013. Revenues of $157,772 for the first quarter of
2014 were higher than $119,429 in 2013, due in part to increased revenue from
the Company's SIAscopy product line.


"During the first quarter the company received the CE Mark for its SIAscopy
products which allows it to start marketing its skin cancer screening technology
in Europe again," said Rob von der Porten, CEO. "In addition, through our
relationship with a distributor in Australia, an application process has started
for certification in Australia, where SIAscopy products have been sold
successfully in the past. Consequently, we believe we will see increased revenue
from our skin cancer screening products in the future," he continued.


About MedX

MedX is headquartered in Mississauga, Ontario (Toronto), and is a global leader
in the design, manufacturing and distribution of quality low level laser and
light therapy technologies for use in numerous medical settings, including
rehab/chiropractic, dental, wound care, and veterinary medicine, providing
patients with drug free and non-invasive treatment of tissue damage and pain.
MedX laser and light products are FDA approved, Health Canada cleared, and CE
Mark approved for use in North America as well as the European Union. MedX's
products include SIMSYS(TM) and MoleMate(TM), which are approved by Health
Canada, and available to Canadian physicians and dermatologists, are FDA
approved for use in the USA and are currently under review for CE approval for
use in Europe, the UK, and Australia, as an optical biopsy that uses patented
technology featuring a hand-held scanner device designed for clinical use that
utilizes light to view beneath suspicious moles or lesions in a pain free,
non-invasive manner, creating images in real-time for physicians and
dermatologists to evaluate all types of moles or lesions within seconds. For
more information log onto www.simsys-molemate.com. For a complete profile of
MedX and its products visit www.medxhealth.com.


This press release does not constitute an offer of any securities for sale. This
press release contains certain forward-looking statements within the meaning of
applicable Canadian securities legislation. These forward-looking statements
involve certain risks and uncertainties that could cause actual results to
differ, including, without limitation, the company's limited operating history
and history of losses, the inability to successfully obtain further funding, the
inability to raise capital on terms acceptable to the company, the inability to
compete effectively in the marketplace, the inability to complete the proposed
acquisition and such other risks that could cause the actual results to differ
materially from those contained in the company's projections or forward-looking
statements. All forward looking statements in this press release are based on
information available to the company as of the date hereof, and the company
undertakes no obligation to update forward-looking statements to reflect events
or circumstances occurring after the date of this press release.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this press release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
MedX Health Corp.
Robert von der Porten
President and CEO
905 670 4428
investor@medxhealth.com
www.medxhealth.com

Medx Health (TSXV:MDX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Medx Health (TSXV:MDX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024